Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.

Prymula, Roman

Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. [electronic resource] - Vaccine Aug 2008 - 4563-70 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0264-410X

10.1016/j.vaccine.2008.05.080 doi


Antibodies, Bacterial--blood
Bacterial Proteins--immunology
Carrier Proteins--immunology
Double-Blind Method
Female
Haemophilus Vaccines--adverse effects
Hepatitis A Vaccines--immunology
Humans
Immunization, Secondary
Immunoglobulin D--immunology
Infant
Lipoproteins--immunology
Male
Pneumococcal Vaccines--adverse effects
Vaccines, Conjugate--immunology